|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BX03
|
|
gptkbp:brand
|
gptkb:Zytiga
|
|
gptkbp:CASNumber
|
154229-18-2
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:BTG_plc
Institute of Cancer Research
|
|
gptkbp:discoveredBy
|
gptkb:Mike_Jarman
|
|
gptkbp:hasMolecularFormula
|
C24H31NO
|
|
gptkbp:hasSMILES
|
CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4C3(CCC(=O)C4)C)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abiraterone
|
|
gptkbp:KEGGID
|
D08928
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Janssen_Biotech
|
|
gptkbp:mechanismOfAction
|
CYP17A1 inhibitor
|
|
gptkbp:molecularWeight
|
349.51 g/mol
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1237
gptkb:DB05812
117331
132971
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
hypertension
hypokalemia
liver function abnormality
|
|
gptkbp:UNII
|
J2U8L2A955
|
|
gptkbp:usedFor
|
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Lynparza
|
|
gptkbp:bfsLayer
|
5
|